Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.02 a new company low.

Within Major Pharmaceutical Preparations industry 550 other companies have achieved higher Quick Ratio than Baudax Bio Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 3584 to 4958.

Explain Quick Ratio?
How much Cash & cash equivalents BXRX�s has?
What are BXRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BXRX Quick Ratio	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3
Y / Y Current Liabilities Change	-10.45 %	12.52 %	-40.96 %	37.63 %	47.31 %
Y / Y Cash & cash equivalent Change	-93.57 %	-72.82 %	-67.01 %	-66.91 %	-77.34 %
Quick Ratio MRQ	0.02	0.07	0.31	0.27	0.27
BXRX's Total Ranking	# 4958	# 3584	# 3239	# 1681	# 3319
Seq. Current Liabilities Change	-6.87 %	65.36 %	-37.37 %	-7.16 %	17.02 %
Seq. Cash & cash equivalent Change	-74.36 %	-62.77 %	-27.69 %	-6.87 %	8.39 %

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 551
Healthcare Sector	# 1108
Overall Market	# 4958

Quick Ratio Statistics
High	Average	Low
2.72	1.2	0.02
(Jun 30 2021)		(Sep 30 2023)

Financial Statements
Baudax Bio Inc 's Current Liabilities	$ 19 Millions	Visit BXRX's Balance sheet
Baudax Bio Inc 's Cash & cash equivalent	$ 0 Millions	Visit BXRX's Balance sheet
Source of BXRX's Sales		Visit BXRX's Sales by Geography

Cumulative Baudax Bio Inc 's Quick Ratio

BXRX's Quick Ratio for the trailling 12 Months

BXRX Quick Ratio	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	-4.19 %	8.73 %	12.6 %	41.28 %	27.36 %
Y / Y Cash & cash equivalent TTM Growth	-71.68 %	-71.98 %	-77.84 %	-76.28 %	-70.78 %
Quick Ratio TTM	0.15	0.22	0.28	0.34	0.51
Total Ranking TTM	# 4057	# 3441	# 4135	# 4007	# 3826
Seq. Current Liabilities TTM Growth	-3.01 %	3.18 %	-10.7 %	7.22 %	10.06 %
Seq. Cash & cash equivalent TTM Growth	-32.77 %	-19.05 %	-27.94 %	-27.78 %	-33.49 %

Quick ratio ranking by company, industry and sector >> Back to BXRX Financial Strength Comparisons >> Go to Compare BXRX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in BXRX's Current Liabilities to $19.05 millions, cumulative Quick Ratio to 0.15 below the BXRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 537 other companies have achieved higher Quick Ratio than Baudax Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3441 to 4057.

Explain Quick Ratio?
How much Cash & cash equivalents BXRX�s has?
What are BXRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 538
Healthcare Sector	# 1089
Within the Market	# 4057

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.16	1.21	0.15
(Sep 30 2021)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2023 MRQ Cash & cash equivalent	Sep 30 2023 MRQ Current Liabilities
Lunai Bioworks Inc	0.05	$ 0.523 Millions	$ 10.096 Millions
Procaps Group S a	0.04	$ 17.514 Millions	$ 401.651 Millions
Inmed Pharmaceuticals Inc	0.04	$ 0.043 Millions	$ 1.046 Millions
Provectus Biopharmaceuticals Inc	0.04	$ 0.367 Millions	$ 9.172 Millions
Actavia Life Sciences Inc	0.04	$ 0.075 Millions	$ 2.052 Millions
Bioxytran Inc	0.03	$ 0.080 Millions	$ 2.333 Millions
Avenue Therapeutics Inc	0.03	$ 0.161 Millions	$ 5.024 Millions
Athersys Inc	0.03	$ 1.020 Millions	$ 38.624 Millions
Emmaus Life Sciences Inc	0.02	$ 1.505 Millions	$ 60.917 Millions
Citius Oncology Inc	0.02	$ 0.027 Millions	$ 1.164 Millions
Hst Global Inc	0.02	$ 0.002 Millions	$ 0.093 Millions
One World Products Inc	0.02	$ 0.095 Millions	$ 4.513 Millions
Vaccinex Inc	0.02	$ 0.127 Millions	$ 6.195 Millions
Baudax Bio Inc	0.02	$ 0.363 Millions	$ 19.051 Millions
Regen Biopharma Inc	0.02	$ 0.121 Millions	$ 6.949 Millions
IMPACT BIOMEDICAL INC.	0.02	$ 0.201 Millions	$ 12.382 Millions
Cytodyn inc	0.02	$ 2.034 Millions	$ 129.053 Millions
Oncotelic Therapeutics Inc	0.02	$ 0.268 Millions	$ 17.111 Millions
Avenir Wellness Solutions Inc	0.01	$ 0.189 Millions	$ 12.789 Millions
Acer Therapeutics Inc	0.01	$ 0.595 Millions	$ 61.670 Millions
Kaya Holdings Inc	0.01	$ 0.060 Millions	$ 7.771 Millions
Axim Biotechnologies Inc	0.01	$ 0.032 Millions	$ 4.278 Millions
Orgenesis Inc	0.00	$ 0.055 Millions	$ 14.302 Millions

Date modified: 2026-08-29T17:41:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.